|View printer-friendly version|
Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy. Abstract Number: 1252 - A0093 Presenter: Mitch Brigell, PhD
Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in NZW Rabbits. Abstract Number: 2719 - B0040. Presenter: Glenwood Gum, PhD
A VE-PTP Antibody Activates Tie2 and Suppresses VEGF-Induced Retinal
Vascular Leakage. Abstract Number: 199 - C0010. Presenter:
Kevin Peters, MD
About Aerpio Pharmaceuticals
AKB-9778 is being developed as a subcutaneous injection for the treatment of non-proliferative diabetic retinopathy and as topical drops for the treatment of primary open-angle glaucoma. AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity causes vascular instability in many diseases including diabetes. AKB-9778 activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist), and may be the most efficient pharmacologic approach to maintain normal Tie2 activation.
ARP-1536, is a humanized monoclonal antibody that inhibits VE-PTP by binding the extracellular domain of VE-PTP. We are evaluating development options for ARP-1536, including once-monthly subcutaneous injection for the treatment of diabetic vascular complications and intravitreal injection for the treatment of advanced diabetic eye disease such as DME or PDR.
Aerpio Pharmaceuticals, Inc.
Michael Rogers, 513-985-1958
Chief Financial Officer